Search

Displaying results 1821 - 1830 of 10000 in total
  1. Drug

    Asparagine

    go.drugbank.com/drugs/DB00174
    ApprovedNutraceuticalWithdrawn

    (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed) … A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase.

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSION
  2. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … [A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the

    Synonyms: N-Hydroxyurea, N-Carbamoylhydroxylamine
  3. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    It was approved for use in Japan in 1995.

  4. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.

  5. Drug

    Rivastigmine

    go.drugbank.com/drugs/DB00989
    ApprovedInvestigational

    Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

    Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN ZEN 13.3MG/24H
  6. Drug

    Eucalyptol

    go.drugbank.com/drugs/DB03852
    ApprovedInvestigationalNutraceutical

    Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. … Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  8. Drug

    Clobazam

    go.drugbank.com/drugs/DB00349
    ApprovedIllicitInvestigational

    Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. … [A256968,A256973] Clobazam has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984.

  9. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    [L38814] In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults. … that it is the first and only oral CGRP antagonist approved for preventative use in migraine.

  10. Drug

    Gallium citrate Ga-67

    go.drugbank.com/drugs/DB06784
    Approved

    Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation